Semaglutide for MASH: the corrected review

In August 2026, Liver International published a correction notice (PMID 42446260) to the November 2025 review "Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis" by Petta, Kim, Targher, and colleagues^[1]. This piece explains what the original review covered, why corrections appear in peer-reviewed literature, and what the erratum means for readers followingsemaglutide data in liver disease.

An erratum changes specific factual items in a published paper while leaving the overall conclusions intact. It is a routine part of the peer-review system, not a signal that a paper's findings have been overturned.

What the original review said

The November 2025 Petta et al. review in Liver International examined the evidence base forsemaglutide 2.4 mg weekly in metabolic dysfunction-associated steatohepatitis (MASH)^[2]. MASH is the inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD), characterised by hepatocyte ballooning, lobular inflammation, and varying degrees of fibrosis. Left untreated, it can progress to cirrhosis and liver failure.

The review drew on the Phase 3 ESSENCE trial, which enrolled patients with biopsy-confirmed MASH and fibrosis stages F2 or F3. At 72 weeks, semaglutide 2.4 mg weekly achieved steatohepatitis resolution without fibrosis worsening in 62.9% of participants versus 34.3% on placebo. Fibrosis improvement without steatohepatitis worsening occurred in 36.8% versus 22.4%^[2]. On the basis of those histological results, the FDA granted accelerated conditional approval for semaglutide in adults with noncirrhotic MASH and moderate-to-advanced fibrosis in August 2025.

The review also summarised metabolic benefits seen in the trial arm: a mean 10.5% body-weight reduction versus 2.0% on placebo, glycaemic improvements in patients with type 2 diabetes, and no new safety signals beyond the class-typical gastrointestinal profile (nausea in 36.2% of the semaglutide group; diarrhoea in 26.9%). Only 2.6% of participants discontinued due to adverse events.

What an erratum is, and what it is not

A published erratum means the journal and authors identified one or more errors after publication and are placing a correction on the scientific record. The PMID 42446260 notice does not include a detailed abstract describing exactly which figures or text were changed; that level of detail typically appears in the full erratum text at the journal.

What an erratum is not: a retraction. A retraction means the journal has withdrawn the paper entirely because its findings cannot be trusted. Errata are far more common and far less serious. They cover typographical errors, mislabelled figures, incorrect statistical values where the corrected values do not change the interpretation, or citation errors. The original review's conclusions on semaglutide's efficacy in MASH stand unless the authors or journal explicitly state otherwise.

Why the underlying trial data are unaffected

The review by Petta and colleagues is a secondary synthesis, not the primary source of the ESSENCE trial data. The biopsy-confirmed histological results underpinning the FDA approval come from the Phase 3 ESSENCE trial publication, which is a separate document in the scientific record^[2]. An erratum to the Petter et al. review does not alter the ESSENCE trial data or the FDA's accelerated approval decision.

Readers who want the primary source for semaglutide's liver efficacy data should consult the ESSENCE trial publication directly, and the original Petta et al. review at its corrected form onLiver International. The correction at PMID 42446260 updates the review record; it is the version readers should cite if referencing this review going forward.

Context: the MASH treatment landscape

Semaglutide joins a short list of agents with liver-specific approval for MASH. The landscape before the August 2025 semaglutide authorisation included resmetirom (a thyroid hormone receptor-beta agonist, FDA-approved March 2024) as the only other approved MASH-specific therapy. Both share a similar positioning: indicated for patients with F2 or F3 fibrosis who have not yet progressed to cirrhosis. Per-country regulatory status forsemaglutide is tracked on the peptide page.

The Petta et al. review remains a useful synthesis of the mechanism, safety, and clinical positioning of semaglutide for MASH. The August 2026 erratum updates the record without altering the substantive conclusions readers rely on when assessing semaglutide as a MASH treatment option.

For broader context on MASH pharmacotherapy and ongoing trial design questions, seesemaglutide MASH NIT endpoints andMASLD pharmacological therapy.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide is a prescription medicine in all jurisdictions where it is approved. Always consult a qualified healthcare professional before using any medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any product.